Active Recombinant Full Length Human PAK4 Protein, DDK-tagged, Biotinylated

• Cat.No.: PAK4-3407HF
• Product Overview: Full-length human PAK4 [1-591(end) amino acids of accession number NP_005875.1] was expressed as N-terminal DYKDDDDK tagged, biotinylated protein (68 kDa) using baculovirus expression system. The protein was purified by using DYKDDDDK tag antibody agarose.

Specification

• Source: Insect (sf21)
• Species: Human
• Tag: DDK
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The activity was measured by off-chip mobility shift assay. The enzyme was incubated with fluorecence-labeled substrate and Mg(or Mn)/ATP. The phosphorylated and unphosphorylated substrates were separated and detected by LabChip™3000.
• Protein length: 1-591(end)
• Purity: 95%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: p21 protein (Cdc42/Rac)-activated kinase 4
• Official Symbol: PAK4
• Synonyms: PAK4
• Protein Refseq: NP_005875.1
• UniProt ID: O96013

Reviews

11/16/2021

The prompt and knowledgeable assistance they offer has greatly enhanced my confidence in using the PAK4 protein.

03/01/2020

I am highly satisfied with the performance and support associated with this protein, as it has proven to be an essential tool in advancing my scientific investigations.

05/18/2016

Its purity and reliability have provided consistent and reliable results in my research.

Q&As

Are there any FDA-approved drugs targeting PAK4?

As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting PAK4.

Are there any diagnostic tests based on PAK4 for cancer screening?

PAK4 is not commonly used as a specific diagnostic marker for cancer screening. Other markers, like PSA for prostate cancer or mammography for breast cancer, are more common.

What are the current clinical trials involving PAK4 inhibitors?

Clinical trials involving PAK4 inhibitors may vary over time. To find the latest information, you should consult clinical trial databases or healthcare professionals.

What are the challenges in developing PAK4 inhibitors for clinical use?

Selectivity and potential side effects are challenges in developing PAK4 inhibitors, which need to be carefully addressed in clinical trials.

How is PAK4-related research contributing to personalized medicine?

PAK4-related research may help identify specific patient populations that could benefit from PAK4-targeted therapies, contributing to personalized treatment approaches.